Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 3/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11261846 | 0.98 | ITGB3 (0.40) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| SCHEMBL1838111 | 0.98 | ITGB3 (0.40) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| Hydrochloric Acid SCHEMBL1844095 | 0.98 | ITGB3 (0.40) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| Hydrochloric Acid SCHEMBL31752969 | 0.96 | GNAO1 (0.42) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| Hydrochloric Acid SCHEMBL7419436 | 0.96 | GNAO1 (0.42) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| SCHEMBL28893 | 0.93 | ITGB3 (0.42) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| Hydrochloric Acid SCHEMBL146163 | 0.91 | ITGB3 (0.41) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| Bromide SCHEMBL11261498 | 0.91 | ITGB3 (0.41) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| SCHEMBL331124 | 0.87 | HRH3 (0.47) | ITGB3ITGA2BHRH3NAMPTFAAH | |
| SCHEMBL4654559 | 0.86 | SLC6A1 (0.45) | ITGB3ITGA2BHRH3NAMPTGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4606803-A1 | KRAS G12D DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12215099-B2 | Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-02-04 | — | — | US | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| US-4345071-A | AZIDOALKYL-HETEROCYCLIC AMIDINE INTERMEDIATES | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1982-08-17 | — | — | US | disclosed |
| US-4229443-A | Derivatives of penicillanic acid | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | ITGB3 2869/4885ITGA2B 3717/4885HRH3 1200/4885 |
| US-12215099-B2 | Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM4, CHRM2 | ITGB3 2863/4885ITGA2B 2873/4885HRH3 94/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | ITGB3 116/4885ITGA2B 88/4885HRH3 1576/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | ITGB3 699/4885ITGA2B 458/4885HRH3 2421/4885 |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | ITGB3 835/4885ITGA2B 479/4885HRH3 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.